ストックスクリーナーアプリを入手
5.68
1.97%
0.11
前日終値:
$5.57
開ける：
$5.64
24時間の取引高:
503.39K
Relative Volume:
0.39
時価総額：
$252.80M
収益：
$3.64M
当期純損益:
$-87.37M
株価収益率:
-1.382
EPS:
-4.11
ネットキャッシュフロー:
$-86.46M
1週間 パフォーマンス:
-4.86%
1か月 パフォーマンス:
+5.38%
6か月 パフォーマンス:
+127.20%
1年 パフォーマンス:
-53.93%
1日の値動き範囲:
$5.545
$5.87
1週間の範囲:
$5.48
$6.03
52週間の値動き範囲:
$2.10
$13.82
Verastem Inc Stock (VSTM) Company Profile
VSTM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.68 | 252.80M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-31 | 繰り返されました | BTIG Research | Buy |
| 2024-09-30 | 開始されました | Guggenheim | Buy |
| 2023-11-21 | 再開されました | BTIG Research | Buy |
| 2023-09-27 | 開始されました | B. Riley Securities | Buy |
| 2023-06-15 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-07 | 再開されました | Alliance Global Partners | Buy |
| 2022-04-29 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-03-09 | 開始されました | Truist | Buy |
| 2021-07-01 | 開始されました | Alliance Global Partners | Buy |
| 2021-05-24 | アップグレード | BTIG Research | Neutral → Buy |
| 2019-06-20 | ダウングレード | BTIG Research | Buy → Neutral |
| 2019-05-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 開始されました | BTIG Research | Buy |
| 2018-05-02 | 開始されました | Seaport Global Securities | Buy |
| 2018-03-08 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-13 | 開始されました | Oppenheimer | Outperform |
| 2017-03-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-09-29 | ダウングレード | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | ダウングレード | Jefferies | Buy → Hold |
| 2015-09-29 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | ダウングレード | Mizuho | Buy → Neutral |
| 2015-09-28 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 開始されました | Raymond James | Strong Buy |
| 2015-05-12 | 繰り返されました | UBS | Buy |
| 2015-04-08 | 開始されました | H.C. Wainwright | Buy |
| 2015-01-23 | 繰り返されました | ROTH Capital | Buy |
| 2014-07-08 | 再開されました | Oppenheimer | Perform |
| 2014-02-11 | 開始されました | Mizuho | Buy |
すべてを表示
Verastem Inc (VSTM) 最新ニュース
Verastem Oncology Announces Multiple Data Presentations At Society Of Gynecologic Oncology 2025 Annual Meeting On Women's Cancer - Marketscreener.com
Can This New Ovarian Cancer Drug Transform Treatment? Key Data Reveals Breakthrough Potential - StockTitan
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag - MSN
When the Price of (VSTM) Talks, People Listen - Stock Traders Daily
Financial Snapshot: Analyzing Verastem Inc (VSTM)’s Key Ratio Metrics - The Dwinnex
Verastem Inc (NASDAQ: VSTM) Shares Fall By -4.77 Percent In The Past Week, But How Long Will It Last? - Marketing Sentinel
The time has not yet come to remove your chips from the table: Verastem Inc (VSTM) - SETE News
Recent Insider Activity Could Benefit Verastem Inc (VSTM) - Knox Daily
Verastem CEO Dan Paterson sells shares worth $4,890 - MSN
Verastem CEO Dan Paterson sells shares worth $4,890 By Investing.com - Investing.com Canada
Verastem, Inc. (NASDAQ:VSTM) Shares Acquired by JPMorgan Chase & Co. - Defense World
Verastem (NASDAQ:VSTM) Given New $9.00 Price Target at B. Riley - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Sees Large Increase in Short Interest - MarketBeat
Financial Metrics Check: Verastem Inc (VSTM)’s Ratios for Trailing Twelve Months - The Dwinnex
B. Riley Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) Stock - Defense World
Brokerages Set Verastem, Inc. (NASDAQ:VSTM) PT at $13.38 - MarketBeat
Vanguard Group Inc. Increases Stake in Verastem Inc. - GuruFocus.com
Verastem price target raised to $9 from $7 at B. Riley - MSN
B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating -January 31, 2025 at 09:19 am EST - Marketscreener.com
Verastem Licenses Investigational Cancer Drug VS-7375 from GenFleet, Shares Rise 4.1% – Market - HPBL
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference - Yahoo Finance
Verastem Exercises Option for VS-7375 Targeting RAS Pathway Driven CancersVerastem, Inc. (NASDAQ:VSTM) has announced the exercise of its option with regards to VS-7375, which is an oral and selective KRAS G12D (ON/OFF) inhibitor. This move signif - Defense World
Guggenheim Reiterates Buy Rating for Verastem (NASDAQ:VSTM) - Defense World
Verastem's (VSTM) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Mizuho maintains Verastem stock outperform with $9 target By Investing.com - Investing.com Australia
Mizuho maintains Verastem stock outperform with $9 target - MSN
Cantor Fitzgerald Estimates Verastem FY2025 Earnings - Defense World
Verastem Stock Soars 46% After FDA Grants Priority Review for Cancer Treatment – Market - HPBL
Cantor Fitzgerald Forecasts Verastem FY2025 Earnings - MarketBeat
Verstem avutometinib and defactinib combo gains FDA priority review - Seeking Alpha
Verastem Expands Oncology Pipeline with VS-7375 Acquisition - TipRanks
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
Barclays PLC Acquires 47,094 Shares of Verastem, Inc. (NASDAQ:VSTM) - MarketBeat
KRAS Inhibitors Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines - Barchart
Verastem appoints new COO with extensive biotech experience By Investing.com - Investing.com South Africa
Verastem appoints new COO with extensive biotech experience - Investing.com India
Verastem Appoints Matthew E. Ros as COO - TipRanks
Verastem Secures $150 Million Note Purchase Agreement with Oberland Capital - Defense World
Verastem stock retains Buy rating as KRASG12D program and LGSOC launch gain traction - Investing.com Canada
Verastem Inc (VSTM) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):